Lancet Genomic Medicine Series: Pharmacogenomics for Individualizing Drug Therapy
This Lancet review synthesizes the evidence for using genetic variation to personalize drug therapy, covering pharmacokinetic and pharmacodynamic mechanisms, clinical trial data, and implementation efforts. The authors describe how variants affecting drug-metabolizing enzymes and transporters can predict both efficacy and adverse effects, while noting the challenges of translating genomic findings into routine clinical practice. It serves as a foundational reference for laboratories building or expanding pharmacogenomic testing programs.
The original study
Pharmacogenomics.
- Authors
- Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, et al.
- Journal
- Lancet (London, England)
- Type
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PMID
- 31395440
Original abstract
Genomic medicine, which uses DNA variation to individualise and improve human health, is the subject of this Series of papers. The idea that genetic variation can be used to individualise drug therapy-the topic addressed here-is often viewed as within reach for genomic medicine. We have reviewed general mechanisms underlying variability in drug action, the role of genetic variation in mediating beneficial and adverse effects through variable drug concentrations (pharmacokinetics) and drug actions (pharmacodynamics), available data from clinical trials, and ongoing efforts to implement pharmacogenetics in clinical practice.